These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38154616)

  • 21. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
    Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
    Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
    de la Rocha C; Cid-López MA; Venegas-López BI; Gómez-Méndez SC; Sánchez-Ortiz A; Pérez-Ríos AM; Llamas-Velázquez RA; Meza-Acuña AI; Vargas-Íñiguez B; Rosales-Galván D; Tavares-Váldez A; Luna-Gudiño N; Hernández-Puente CV; Milenkovic J; Iglesias-Palomares C; Méndez-Del Villar M; Gutiérrez-Dieck GA; Valderrábano-Roldán CG; Mercado-Cerda J; Robles-Bojórquez JG; Mercado-Sesma AR
    BMC Infect Dis; 2022 Dec; 22(1):917. PubMed ID: 36482326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
    Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
    Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
    Buonfrate D; Chesini F; Martini D; Roncaglioni MC; Ojeda Fernandez ML; Alvisi MF; De Simone I; Rulli E; Nobili A; Casalini G; Antinori S; Gobbi M; Campoli C; Deiana M; Pomari E; Lunardi G; Tessari R; Bisoffi Z
    Int J Antimicrob Agents; 2022 Feb; 59(2):106516. PubMed ID: 34999239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
    Wada T; Hibino M; Aono H; Kyoda S; Iwadate Y; Shishido E; Ikeda K; Kinoshita N; Matsuda Y; Otani S; Kameda R; Matoba K; Nonaka M; Maeda M; Kumagai Y; Ako J; Shichiri M; Naoki K; Katagiri M; Takaso M; Iwamura M; Katayama K; Miyatsuka T; Orihashi Y; Yamaoka K;
    Front Med (Lausanne); 2023; 10():1139046. PubMed ID: 37283627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-specific prevention of COVID-19 during vaccination against a new coronavirus infection: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial].
    Avdeeva MG; Belousova ON; Orlova EA; Khamitov RF; Shvarts YG; Kravchenko IE
    Ter Arkh; 2022 Dec; 94(11):1268-1277. PubMed ID: 37167165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
    Mohan A; Tiwari P; Suri TM; Mittal S; Patel A; Jain A; Velpandian T; Das US; Boppana TK; Pandey RM; Shelke SS; Singh AR; Bhatnagar S; Masih S; Mahajan S; Dwivedi T; Sahoo B; Pandit A; Bhopale S; Vig S; Gupta R; Madan K; Hadda V; Gupta N; Garg R; Meena VP; Guleria R
    J Infect Chemother; 2021 Dec; 27(12):1743-1749. PubMed ID: 34483029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study).
    Kinoshita T; Shinoda M; Nishizaki Y; Shiraki K; Hirai Y; Kichikawa Y; Tsushima K; Shinkai M; Komura N; Yoshida K; Kido Y; Kakeya H; Uemura N; Kadota J
    BMC Med; 2022 Sep; 20(1):342. PubMed ID: 36163020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.